Media headlines about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.2531030905378 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Oramed Pharmaceuticals (NASDAQ:ORMP) opened at $8.42 on Friday. The stock has a market capitalization of $120.46, a PE ratio of -10.94 and a beta of 1.09. Oramed Pharmaceuticals has a 12-month low of $5.85 and a 12-month high of $11.34.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Wednesday, November 29th. The biotechnology company reported ($0.20) EPS for the quarter. Oramed Pharmaceuticals had a negative return on equity of 49.94% and a negative net margin of 169.17%. analysts anticipate that Oramed Pharmaceuticals will post -1.31 EPS for the current fiscal year.
A number of equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Thursday, October 5th. ValuEngine raised Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Oramed Pharmaceuticals in a research report on Tuesday.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/19/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-oramed-pharmaceuticals-ormp-share-price.html.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.